Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kowa Releases Top-line Results For Dyslipidemia Trial
Headquartered in Nagoya, Japan, Kowa has announced that the new data showed that Pitavastatin may provide a new treatment option for patients with dyslipidemia. It may also be
Headquartered in Nagoya, Japan, Kowa has announced that the new data showed that Pitavastatin may provide a new treatment option for patients with dyslipidemia. It may also be
IPSOGEN, a cancer profiler that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, has announced that it has successfully carried out a E2.5 million
MDS Nordion has announced that the company and the Karpov Institute have agreed to combine their respective expertise and resources to explore the development of a commercialization plan,
Petition requested FDA to require all in vitro diagnostic tests intended for use in drug or biologic therapeutic decision-making to be held to the same scientific and regulatory
Boehringer Ingelheim has announced that the company has presented telmisartan and amlodipine combination data at the 19th Scientific Meeting of the European Society of Hypertension, Milan, Italy. The
Tennessee based, Cumberland has announced that FDA has approved Caldolor, an intravenous formulation of ibuprofen, through a priority review. Caldolor is indicated for the management of mild to
PolyMedix has declared that it has received a phase-II Small Business Innovation Research (SBIR) grant in the amount of $923,080. The fund will be disbursed over a period
Novo Nordisk products, previously reported as stolen in North Carolina, has resurfaced recently at a medical center in Houston. Three lots of 10ml vials of insulin, marketed under
New Jersey-based Merck has issued the following statement in response to the FDA’s updated information on leukotriene inhibitors, including Singulair (montelukast sodium). Since the introduction of Singulair, the
Biosense has declared that it will be part of a public/private collaboration to fund a global clinical trial, to compare catheter ablation to medical therapy in treating atrial